Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jul;125(2):190-199.
doi: 10.1038/s41416-021-01334-9. Epub 2021 Apr 6.

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

Thomas Decaens  1 , Carlo Barone  2 , Eric Assenat  3 , Martin Wermke  4 , Angelica Fasolo  5 , Philippe Merle  6 , Jean-Frédéric Blanc  7 , Véronique Grando  8 , Angelo Iacobellis  9 , Erica Villa  10 , Joerg Trojan  11 , Josef Straub  12 , Rolf Bruns  13 , Karin Berghoff  14 , Juergen Scheele  15 , Eric Raymond  16 , Sandrine Faivre  17
Affiliations
Clinical Trial

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

Thomas Decaens et al. Br J Cancer. 2021 Jul.

Erratum in

Abstract

Background: This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression.

Methods: Eligible adults had aHCC, progression after ≥4 weeks of sorafenib, and, for Phase 2 only, MET overexpression. Tepotinib was administered once daily at 300 or 500 mg in Phase 1b ('3 + 3' design), and at the recommended Phase 2 dose (RP2D) in Phase 2. Primary endpoints were dose-liming toxicities (DLTs; Phase 1b) and 12-week investigator-assessed progression-free survival (PFS; Phase 2).

Results: In Phase 1b (n = 17), no DLTs occurred and the RP2D was confirmed as 500 mg. In Phase 2 (n = 49), the primary endpoint was met: 12-week PFS was 63.3% (90% CI: 50.5-74.7), which was significantly greater than the predefined null hypothesis of ≤15% (one-sided binomial exact test: P < 0.0001). Median time to progression was 4 months. In Phase 2, 28.6% of patients had treatment-related Grade ≥3 adverse events, including peripheral oedema and lipase increase (both 6.1%).

Conclusions: Tepotinib was generally well tolerated and the RP2D (500 mg) showed promising efficacy and, therefore, a positive benefit-risk balance in sorafenib pretreated aHCC with MET overexpression.

Trial registration: ClinicalTrials.gov: NCT02115373.

PubMed Disclaimer

Conflict of interest statement

T.D. provided consulting for Bristol-Myers Squibb, AstraZeneca, Ipsen, Bayer, Eisai and Becton Dickinson; received research grants from Genoscience and ArQule, and travel grants from Merck. C.B. attended speaker’s bureau for Servier; received research grants from Merck-Serono and travel grants from Daiichi-Sankyo. P.M. has participated in advisory boards for Bayer, Eisai, Exelixis, Ipsen, Lilly, Onxeo, Roche, AstraZeneca, Bristol-Myers Squibb and Merck Sharp & Dohme. J.-F.B. has provided consulting for Bayer, Ipsen, Eisai, Bristol-Myers Squibb, Roche and AstraZeneca. J.T. has participated in advisory boards and speakers’ bureau for Merck-Serono, Roche, Lilly, Eisai and Ipsen, and received travel grants from Roche. E.R. has provided consulting for Genoscience and SCOR, and holds stocks with both companies. S.F. has participated in advisory boards for Bayer, Eisai, Ipsen, Merck-Serono and Roche, and attended speakers’ bureau for Bayer, Eisai and Ipsen. E.A., M.W., A.F., V.G., A.I. and E.V. have nothing to disclose. J.S., R.B. and K.B. are employees of Merck KGaA, Darmstadt, Germany, and hold stock with the company. J.Sc. is an employee of Merck KGaA, Darmstadt, Germany.

Figures

Fig. 1
Fig. 1. Percentage of patients progression free at 12 weeks according to investigator assessment in Phase 2.
Data are shown for the overall population and patient subgroups.aModerate (2+) or strong (3+) staining intensity for MET on IHC in the majority (≥50%) of tumour cells; bMET amplification defined as MET:CEP7 ratio ≥2 or mean gene copy number ≥5; cAFP was missing for two patients (12-week PFS in these patients was 100%). AFP alpha-fetoprotein; CI confidence interval, EHS extrahepatic spread, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, HCV hepatitis C virus, IHC immunohistochemistry, PFS progression-free survival.
Fig. 2
Fig. 2. Kaplan–Meier curves for PFS, TTP and OS in Phase 2.
a Investigator-assessed PFS, b investigator-assessed TTP, c OS. CI confidence interval, OS overall survival, PFS progression-free survival, TTP time to progression.
Fig. 3
Fig. 3. Best relative change in target lesions in Phase 2.
Shading indicates MET IHC status: 2+ (white) or 3+ (black). Patients with MET amplification are labelled. Inset table shows overall response and disease control rates. aModerate (2+) or strong (3+) staining intensity for MET on IHC in the majority (≥50%) of tumour cells; MET amplification defined as MET:CEP7 ratio ≥2 or mean gene copy number ≥5. CI confidence interval, DCR disease control rate, IHC immunohistochemistry, ORR objective response rate, SOLD sum of longest diameter.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2016;2:16018. doi: 10.1038/nrdp.2016.18. - DOI - PubMed
    1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019;16:589–604. doi: 10.1038/s41575-019-0186-y. - DOI - PMC - PubMed
    1. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155–2166. doi: 10.1111/liv.12818. - DOI - PMC - PubMed
    1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 69, 182–236 (2018). - PubMed

Publication types

MeSH terms

Associated data